MetLife (MET) earnings call transcript summary & sentiment

Our read on the 6 August 2026 earnings call

Overall tone

Positive

Executive Summary

MetLife delivered strong Q2 2026 financial results, highlighted by a 20% year-over-year increase in adjusted EPS to $2.43 and an adjusted ROE of 17%, reaching the top end of its annual target range.

Core Signals

Revenue Growth & Demand: Adjusted premiums, fees, and other revenues (excluding PRT) increased 5% year-over-year, while total sales grew 7% behind broad-based international demand.

Bullish Signals

Group Benefits adjusted earnings increased 25% year-over-year, supported by a 79% group life mortality ratio that beat internal target ranges.

Risk Signals

Pre-tax variable investment income missed quarterly run rates due to depressed private equity returns of 0.8%, pulling total RIS investment spread down to 97 bps.

Q&A Signals

Repeated analyst topics: Analysts focused heavily on group life mortality normalization timelines, pricing adjustments, second-half PRT pipeline expectations, and private equity allocation strategies.

Key Investor Debate

The primary debate among equity analysts centers on whether exceptionally high Group Life underwriting margins will spark competitive repricing during upcoming three-to-five-year contract renewal cycles.

Analyst Takeaway

MetLife demonstrated solid operational leverage and execution across its dual capital-light and capital-driven earnings engines, producing top-tier returns despite temporary investment spread headwinds.